Showing results (31-40 of 136) with videos related to
Sort By:
Pageof 14
Future Oncology (London, England)|September 28, 2020
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphomaMartin Dreyling, Constantine S Tam, Michael Wang, et al.Journal of Basic and Clinical Physiology and Pharmacology|April 11, 2023
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinibGioacchino Catania, Rita Tavarozzi, Giacomo Maria Pini, et al.Cancer|August 28, 2003
Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3Alessandra Cuttica, Francesco Zallio, Marco Ladetto, et al.Leukemia & Lymphoma|January 7, 2016
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)Benedetto Bruno, Holger W Auner, Gösta Gahrton, et al.British Journal of Haematology|May 25, 2002
Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting systemClaudia Voena, Giovanni Locatelli, Claudia Castellino, et al.JCO Oncology Practice|April 27, 2026
Attitudes, Practices, and Barriers to Spiritual Care for Patients With Cancer: An International SurveyCarla Ida Ripamonti, Junita Henry, Christina M Puchalski, et al.BMC Cancer|August 25, 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatmentStephanie Herold, Christian Schmidt, Carlo Visco, et al.Experimental Hematology|September 10, 2003
Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma cloneMarco Ladetto, Barbara Mantoan, Irene Ricca, et al.Cancers|November 25, 2023
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical PracticeRita Tavarozzi, Giulia Zacchi, Daniela Pietrasanta, et al.Nature Communications|April 21, 2015
Epigenomic evolution in diffuse large B-cell lymphomasHeng Pan, Yanwen Jiang, Michela Boi, et al.Pageof 14